IL142284A0 - A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor - Google Patents

A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor

Info

Publication number
IL142284A0
IL142284A0 IL14228499A IL14228499A IL142284A0 IL 142284 A0 IL142284 A0 IL 142284A0 IL 14228499 A IL14228499 A IL 14228499A IL 14228499 A IL14228499 A IL 14228499A IL 142284 A0 IL142284 A0 IL 142284A0
Authority
IL
Israel
Prior art keywords
agent
lymphotoxin
receptor
binding
blocks
Prior art date
Application number
IL14228499A
Other languages
English (en)
Original Assignee
Biogen Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ Emory filed Critical Biogen Inc
Publication of IL142284A0 publication Critical patent/IL142284A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • C07K16/242Lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL14228499A 1998-10-09 1999-10-08 A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor IL142284A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (1)

Publication Number Publication Date
IL142284A0 true IL142284A0 (en) 2002-03-10

Family

ID=22296372

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14228499A IL142284A0 (en) 1998-10-09 1999-10-08 A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
IL142284A IL142284A (en) 1998-10-09 2001-03-27 A pharmaceutical preparation containing a factor that blocks the binding of lymphotexin-B to its receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142284A IL142284A (en) 1998-10-09 2001-03-27 A pharmaceutical preparation containing a factor that blocks the binding of lymphotexin-B to its receptor

Country Status (27)

Country Link
US (3) US20020001585A1 (no)
EP (1) EP1119370B1 (no)
JP (2) JP4713738B2 (no)
KR (1) KR100888832B1 (no)
CN (1) CN1200733C (no)
AT (1) ATE329618T1 (no)
AU (1) AU777492C (no)
BR (1) BR9915025A (no)
CA (1) CA2344049C (no)
CY (1) CY1105059T1 (no)
CZ (1) CZ20011272A3 (no)
DE (1) DE69931944T2 (no)
DK (1) DK1119370T3 (no)
EA (1) EA006703B1 (no)
EE (1) EE04661B1 (no)
ES (1) ES2267294T3 (no)
HU (1) HUP0103773A3 (no)
IL (2) IL142284A0 (no)
IS (1) IS2514B (no)
NO (1) NO326905B1 (no)
NZ (1) NZ510560A (no)
PL (1) PL195264B1 (no)
PT (1) PT1119370E (no)
SG (1) SG121778A1 (no)
SK (1) SK4662001A3 (no)
TR (1) TR200100974T2 (no)
WO (1) WO2000021558A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
AU777492C (en) * 1998-10-09 2005-05-26 Biogen Ma Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60143231D1 (de) * 2000-04-12 2010-11-18 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
CA2086264C (en) 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
EP1407781A1 (en) 1995-01-26 2004-04-14 Biogen, Inc. Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
TR199901636T2 (xx) * 1996-10-25 1999-09-21 Biogen, Inc. �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
AU777492C (en) * 1998-10-09 2005-05-26 Biogen Ma Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA

Also Published As

Publication number Publication date
CN1200733C (zh) 2005-05-11
CN1323223A (zh) 2001-11-21
EP1119370B1 (en) 2006-06-14
WO2000021558A9 (en) 2001-05-25
HUP0103773A2 (hu) 2002-01-28
HUP0103773A3 (en) 2003-10-28
AU6296499A (en) 2000-05-01
TR200100974T2 (tr) 2001-11-21
CZ20011272A3 (cs) 2001-09-12
SG121778A1 (en) 2006-05-26
AU777492B2 (en) 2004-10-21
DE69931944T2 (de) 2007-02-08
NZ510560A (en) 2003-09-26
PL347177A1 (en) 2002-03-25
WO2000021558A1 (en) 2000-04-20
AU777492C (en) 2005-05-26
ATE329618T1 (de) 2006-07-15
IS5882A (is) 2001-03-09
PT1119370E (pt) 2006-09-29
CA2344049A1 (en) 2000-04-20
NO20011757D0 (no) 2001-04-06
DE69931944D1 (de) 2006-07-27
EE200100211A (et) 2002-08-15
NO326905B1 (no) 2009-03-16
KR20010080073A (ko) 2001-08-22
SK4662001A3 (en) 2001-11-06
EA200100430A1 (ru) 2001-10-22
KR100888832B1 (ko) 2009-03-17
ES2267294T3 (es) 2007-03-01
BR9915025A (pt) 2001-08-14
IL142284A (en) 2009-11-18
EP1119370A1 (en) 2001-08-01
US7452530B2 (en) 2008-11-18
US20090087403A1 (en) 2009-04-02
JP2010155852A (ja) 2010-07-15
EE04661B1 (et) 2006-08-15
DK1119370T3 (da) 2006-10-02
JP2002527403A (ja) 2002-08-27
EA006703B1 (ru) 2006-02-24
US20040198635A1 (en) 2004-10-07
CA2344049C (en) 2009-12-15
PL195264B1 (pl) 2007-08-31
NO20011757L (no) 2001-06-08
US20020001585A1 (en) 2002-01-03
JP4713738B2 (ja) 2011-06-29
CY1105059T1 (el) 2010-03-03
IS2514B (is) 2009-06-15

Similar Documents

Publication Publication Date Title
IL142284A0 (en) A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
HU1400409D0 (hu) Renin inhibitort tartalmazó kombinációs készítmények
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
UA41995C2 (uk) Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
HUP0102543A3 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
IL130714A0 (en) Dosage forms and method for ameliorating male erectile dysfunction
HUP0102477A3 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
IL110045A (en) Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
EP0866656A4 (en) INHIBITING THE ALPHA TUMORNESCROSE FACTOR
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
GB9700817D0 (en) Drug delivery composition for the nasal administration of antiviral agents
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
HK1035719A1 (en) Azabicyclic compounds, pharmaceutical composition containing them and their medicinal use
HUP0004407A1 (hu) Eprosartant tartalmazó, azonnali és módosított hatóanyag-felszabadítású, orális adagolású készítmények és előállítási eljárásaik
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
HUP0301578A3 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
HK1029099A1 (en) 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
HUT74745A (en) Pharmaceutical compositions containing p antagonist for treating pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia